The Russian company has been allowed to test their

drug from cancer in the United States

Russian biopharmaceutical company "Inkuron", developing innovative anti-cancer drugs, has received approval from the U.S. Administration of Quality Supervision Food and Drug Administration (FDA) for clinical trials of the drug CBL0137 for the treatment of patients with advanced malignant tumors, reports of "MER".

"Receiving FDA approval for the study of innovative molecules in the USA Russian start-ups is a precedent in the case of the Russian practice," — said General Director of Management Company "Bioprocess Capital Partners" Vladimir prostheses, which is cited in the report. 

"Inkuron" — a Russian company, founded in 2010 by the "Bioprocess Capital Ventures", created with the participation of RVC capital and Vnesheconombank, and private investor Cleveland BioLabs. The company is a member of the project "Skolkovo". "Inkuron" developing a radically new anti-cancer drugs based on Kuraksin — small molecules with potentially wide range of therapeutic applications. Kuraksin may also be used to treat certain autoimmune diseases and inflammatory conditions.

Management Company "Bioprocess Capital Partners" is the trustee of the fund, "Bioprocess Capital Ventures." The Fund invests in innovative projects in the field of biotechnology and fine chemistry, the size of the fund — three billion rubles.

Like this post? Please share to your friends: